HC Wainwright Predicts Lower Earnings for Zenas BioPharma

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – Analysts at HC Wainwright lowered their Q2 2026 EPS estimates for Zenas BioPharma in a report released on Friday, May 15th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($1.46) per share for the quarter, down from their previous estimate of ($1.29). HC Wainwright has a “Buy” rating and a $44.00 price objective on the stock. The consensus estimate for Zenas BioPharma’s current full-year earnings is ($4.25) per share. HC Wainwright also issued estimates for Zenas BioPharma’s Q3 2026 earnings at ($1.46) EPS, Q4 2026 earnings at ($0.70) EPS, FY2026 earnings at ($5.06) EPS, FY2027 earnings at ($4.34) EPS, FY2028 earnings at ($3.84) EPS, FY2029 earnings at ($3.18) EPS and FY2030 earnings at ($1.79) EPS.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same quarter last year, the business posted ($0.80) earnings per share.

ZBIO has been the subject of a number of other research reports. Morgan Stanley lifted their target price on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday. Guggenheim lifted their target price on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a research note on Thursday. Zacks Research raised shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday. Finally, Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $44.29.

Zenas BioPharma Trading Down 7.8%

NASDAQ ZBIO opened at $16.91 on Tuesday. Zenas BioPharma has a twelve month low of $8.91 and a twelve month high of $44.60. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -2.00 and a beta of -0.61. The firm’s 50 day moving average price is $21.04 and its two-hundred day moving average price is $26.62.

Hedge Funds Weigh In On Zenas BioPharma

A number of large investors have recently modified their holdings of the stock. Quarry LP lifted its holdings in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after buying an additional 291 shares during the period. Deutsche Bank AG increased its stake in Zenas BioPharma by 4.5% in the fourth quarter. Deutsche Bank AG now owns 12,781 shares of the company’s stock valued at $464,000 after purchasing an additional 554 shares in the last quarter. CWM LLC increased its stake in Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares in the last quarter. Two Sigma Investments LP increased its stake in Zenas BioPharma by 3.9% in the third quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock valued at $452,000 after purchasing an additional 765 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Zenas BioPharma by 5.8% in the third quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock valued at $329,000 after purchasing an additional 818 shares in the last quarter.

Insider Transactions at Zenas BioPharma

In related news, Director Fairmount Funds Management Llc acquired 150,000 shares of the company’s stock in a transaction dated Tuesday, March 31st. The shares were bought at an average price of $20.00 per share, for a total transaction of $3,000,000.00. Following the acquisition, the director owned 2,359,025 shares in the company, valued at $47,180,500. This trade represents a 6.79% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hongbo Lu purchased 3,768 shares of Zenas BioPharma stock in a transaction on Tuesday, March 31st. The stock was purchased at an average price of $18.63 per share, for a total transaction of $70,197.84. Following the completion of the transaction, the director owned 426,736 shares of the company’s stock, valued at approximately $7,950,091.68. This represents a 0.89% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have purchased 273,768 shares of company stock worth $5,150,198. 22.00% of the stock is currently owned by company insiders.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.